Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clear skin effect on quality of life in moderate to severe plaque psoriasis treated with secukinumab
2015-003701-42Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in plaque psoriasis, sponsored by Novartis. Primary endpoint: DLQI 0/1 response at Week 16. Started Dec 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-003701-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003701-42.